Navidea Biopharmaceuticals Inc Debt/Equity
What is the Debt/Equity of Navidea Biopharmaceuticals Inc?
The Debt/Equity of Navidea Biopharmaceuticals Inc is -0.24
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on NYSEMKT compared to Navidea Biopharmaceuticals Inc
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Companies with debt/equity similar to Navidea Biopharmaceuticals Inc
- Emisphere Technologies has Debt/Equity of -0.42
- Adamis Pharmaceuticals Corp has Debt/Equity of -0.41
- Orca Gold has Debt/Equity of -0.36
- CBD Global Sciences has Debt/Equity of -0.33
- Adynxx has Debt/Equity of -0.26
- Orsu Metals has Debt/Equity of -0.26
- Navidea Biopharmaceuticals Inc has Debt/Equity of -0.24
- Insurance Acquisition has Debt/Equity of -0.22
- RJK Explorations has Debt/Equity of -0.17
- Inspire Semiconductor has Debt/Equity of -0.13
- Cytocom Inc has Debt/Equity of -0.10
- Curative Biosciences has Debt/Equity of -0.10
- Supreme Metals Corp has Debt/Equity of -0.07